Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01338610 · ClinicalTrials.gov registry record · Phase 2
ESBA105 in Patients With Severe Dry Eye
A Phase 2 study of Eyes Dry Chronic, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 334
- Enrollment target
- 1
- Study location
NCT01338610: Completed Phase 2 study of Eyes Dry Chronic, sponsored by Alcon Research.
NCT01338610 is a Phase 2 study of Eyes Dry Chronic that has completed, run by Alcon Research. The registered enrollment target is 334 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (151% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01338610, a Phase 2 study of Eyes Dry Chronic, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 334 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study was to evaluate the efficacy of ESBA105 over vehicle in reducing the ocular symptoms of dry eye disease, as measured by a mean global Visual Analog Scale (VAS) discomfort score.
Primary Outcome
An electronic Visual Analog Scale (eVAS) was used by the subject to assess ocular discomfort, both frequency and severity, at Day 0 (pre-treatment) and daily thereafter for 28 days. Assessments were entered into a LogPad® (handheld electronic device). The VAS frequency score ranged from 0 (rarely) to 100 (all the time), and the VAS severity score ranged from 0 (very mildly uncomfortable) to 100 (very severely uncomfortable). The Global Ocular Discomfort Score is a composite of the frequency and
Conditions Studied
Interventions
- BIOLOGICAL ESBA105 ophthalmic solution
- OTHER ESBA105 vehicle
Study Locations (1)
Texas
- Contact Alcon Call Center for Trial Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
What the finished NCT01338610 record still lists
NCT01338610 is an interventional study that assigns participants to a tested intervention. The registered 334 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (151% higher).
The record links to 1 condition, with Eyes Dry Chronic appearing as the primary indexed condition, and to 2 interventions - of which ESBA105 ophthalmic solution is the first listed.
NCT01338610 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01338610 about?
NCT01338610 is a clinical study titled "ESBA105 in Patients With Severe Dry Eye". The purpose of this study was to evaluate the efficacy of ESBA105 over vehicle in reducing the ocular symptoms of dry eye disease, as measured by a mean global Visual Analog Scale (VAS) discomfort score.
What is the current status of trial NCT01338610?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 334 participants. The study started on 2011-06. Estimated completion is 2012-02.
What conditions does trial NCT01338610 study?
This clinical trial studies the following conditions: Eyes Dry Chronic.
What interventions are being tested in trial NCT01338610?
The interventions under investigation include: ESBA105 ophthalmic solution (BIOLOGICAL), ESBA105 vehicle (OTHER).
Who is sponsoring clinical trial NCT01338610?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01338610 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eyes Dry Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01338610's enrollment target sits among peer trials
334 143rd of 2000 higher than 1,857 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05131672 · 334 participants · NA
Cast or Operation for Medial Epicondyle Fracture Treatment in Children
- NCT05131685 · 334 participants · NA
Distal Radius Interventions for Fracture Treatment
- NCT05546931 · 334 participants · NA
Mobile Health Program for Rural Hypertension
- NCT05722197 · 334 participants · NA
Assessment of Emotion Regulation Strategies Used When Suicidal
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia